Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody–drug conjugates: in search of partners of choice
Jesús Fuentes‐Antrás, Sofia Genta, Abi Vijenthira, et al.
Trends in cancer (2023) Vol. 9, Iss. 4, pp. 339-354
Open Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

Precision treatment in advanced hepatocellular carcinoma
Xupeng Yang, Chen Yang, Shu Zhang, et al.
Cancer Cell (2024) Vol. 42, Iss. 2, pp. 180-197
Open Access | Times Cited: 124
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 66
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Qing Wei, Peijing Li, Teng Yang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 54
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial
Yakun Wang, Jifang Gong, Airong Wang, et al.
EClinicalMedicine (2024) Vol. 68, pp. 102415-102415
Open Access | Times Cited: 29
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 26
Targeting ATR in patients with cancer
Natalie Ngoi, Patrick G. Pilié, Daniel J. McGrail, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 278-293
Closed Access | Times Cited: 24
Anticancer activities of natural antimicrobial peptides from animals
Baozhen Qu, Jiangshui Yuan, Xueli Liu, et al.
Frontiers in Microbiology (2024) Vol. 14
Open Access | Times Cited: 21
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Targeting Trop-2 in cancer: Recent research progress and clinical application
Shuying Qiu, Jianping Zhang, Zhuo Wang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188902-188902
Open Access | Times Cited: 34
Development of antibody‐drug conjugates in cancer: Overview and prospects
Dan‐Yun Ruan, Hao‐Xiang Wu, Qi Meng, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 3-22
Open Access | Times Cited: 27
Precision cancer medicine: Concepts, current practice, and future developments
Anders Edsjö, Louise Holmquist, Birgit Geoerger, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 4, pp. 455-481
Open Access | Times Cited: 26
Homogeneous multi-payload antibody–drug conjugates
Toby Journeaux, Gonçalo J. L. Bernardes
Nature Chemistry (2024) Vol. 16, Iss. 6, pp. 854-870
Closed Access | Times Cited: 13
Therapeutic synthetic and natural materials for immunoengineering
Anna Slezak, Kevin Chang, Samir Hossainy, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 4, pp. 1789-1822
Open Access | Times Cited: 11
Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
Hirokazu Suzuki, Shotaro Nagase, C. Saito, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 3, pp. 257-271
Open Access | Times Cited: 11
Reprogramming natural killer cells for cancer therapy
Kexin Wang, Linqin Wang, Yiyun Wang, et al.
Molecular Therapy (2024) Vol. 32, Iss. 9, pp. 2835-2855
Closed Access | Times Cited: 10
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
Puguang Yu, Chunming Zhu, Xiangyun You, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 10
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 9
Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
Marjorie A. Shapiro
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 9
Next-generation combination approaches for immune checkpoint therapy
Sangeeta Goswami, Kristen E. Pauken, Linghua Wang, et al.
Nature Immunology (2024) Vol. 25, Iss. 12, pp. 2186-2199
Closed Access | Times Cited: 9
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer
Heather L. McArthur, Sara M. Tolaney, Rebecca Dent, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access | Times Cited: 1
Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report
Yong Wu, Lingfang Xia, Chunyan Song, et al.
Journal of Ovarian Research (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Nityanand Srivastava, Salman Sadullah Usmani, Rajasekaran Subbarayan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 22
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
Aleksei Kondrashov, Surendra Sapkota, Aditya Sharma, et al.
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2160-2160
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top